MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, April 3, 2012

Synthetic Biologics — formerly Adeona Pharmaceuticals — set to start phase-two test of multiple sclerosis drug

Ann Arbor-based Synthetic Biologics Inc., formerly known as Adeona Pharmaceuticals Inc., announced today that it has completed enrollment of 164 patients for a phase-two U.S. Food and Drug Administrationtrial of a drug to treat multiple sclerosis.
Synthetic Biologics (NYSE Amex: SYN) has received more than $8 million in grants to help bring to market the drug, Trimesta, which is taken orally. The company said the money will be sufficient to fund the trial to its completion.
The randomized, double-blind trial will be at 15 sites in the U.S. If results are promising, Synthetic Biologics will conduct a larger phase-three trial — the last step before commercialization.
Trimesta targets a form of MS known as relapsing-remitting MS, which affects women.

Comments are appreciated. Note that All comments are moderated 
 If not yet receiving our weekly e-Newsletter Click here to: REGISTER -


1 comment:

Anonymous said...

"Trimesta targets a form of MS known as relapsing-remitting MS, which affects women."
Is the the pharm company or the author that is unaware that RRMS affects men too?